Form 4: Athira Pharma Director Joseph Edelman Acquires Stock Options

Director Joseph Edelman acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024.

Summary

• On May 24, 2024, Joseph Edelman, a director of Athira Pharma, Inc., acquired 20,900 stock options at an exercise price of $2.64.
• These options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
• The options expire on May 23, 2034.
• The options were granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
• Following the transaction, Edelman directly owns 20,900 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing the grant of stock options. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about an insider transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could potentially impact shareholder sentiment, depending on how it's perceived.

Key Dates